Robot-based Therapy for Upper Limb Sensorimotor Impairments After Stroke

July 19, 2022 updated by: Prof Geert Verheyden, KU Leuven

Robot-based Therapy for Upper Limb Sensorimotor Impairments in the Chronic Phase After Stroke: a Pilot Study

After a stroke, more than two out of three patients experience problems with upper limb movement and sensation. Current evidence on treatment of upper limb sensory impairments is scarce and shows unclear results. Robot-based therapy has been increasingly used to treat upper limb motor impairments, with similar positive results as compared to conventional therapy. This study aims to investigate a novel robot-based therapy program for treatment of upper limb sensory impairments. The therapy program consists of 10 one-hour session spread over 4 weeks and will be evaluated for its effect in 20 chronic stroke patients. The investigators hypothesize that a 4-week robot-based therapy program can improve upper limb sensation and movement.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Up to 70% of stroke survivors show upper limb impairments consisting of motor and/or somatosensory impairments. These impairments often persist well into the chronic stage, and may lead to significant limitations in activities of daily living and may negatively affect quality of life. Different interventions have been investigated to treat upper limb motor impairments, including robot-based therapy, which shows similar positive results as compared to conventional therapy. Evidence on interventions for somatosensory impairments is scarce and often of low quality. This study therefore aims to evaluate the effect of a robot-based therapy program on sensorimotor function of the upper limb in a group of 20 chronic stroke patients.

The robot-based therapy will be provided using the Kinarm End-Point Lab (BKIN Technologies Ltd., Canada) and consists of passive and active therapy tasks for proprioception and sensory processing. The therapy consists of 10 one-hour sessions spread over 4 weeks. Clinical and robot-based motor and somatosensory assessments will be performed at 4 time points: twice at baseline, once at mid intervention, and once after 10 hours of therapy. The investigators hypothesize to find improvement in both upper limb motor and somatosensory function after the therapy program. The results from this pilot study will provide a basis for further research.

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Leuven, Belgium, 3001
        • KU Leuven

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • At least 18 years old
  • A first-ever unilateral, supratentorial stroke (as defined by WHO)
  • In the chronic phase after stroke (i.e. being at least 6 months after stroke)
  • Motor deficits of the upper limb (Fugl-Meyer Motor Assessment - Upper Extremity < 60/66)
  • Somatosensory deficits of the upper limb (Erasmus modified Nottingham Sensory Assessment < 36/40)
  • Ability to perform, at least to some extent, active shoulder abduction and wrist extension against gravity
  • Ability to perform passive and active sensory processing assessment task (primary outcome measure)

Exclusion Criteria:

  • History of previous stroke or TIA
  • Any serious musculoskeletal and/or other neurological conditions
  • Serious communication or cognitive deficits
  • No written informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Robot-based therapy
Chronic stroke patients receiving robot-based therapy
Active and passive therapy tasks for proprioception and sensory processing, with use of the Kinarm End-Point Lab (BKIN Technologies Ltd., Canada)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Kinarm: sensory processing task
Time Frame: Change during 4 weeks of therapy provided at least 6 months after stroke
Newly-developed task on the Kinarm End-Point Lab used to assess passive and active sensory processing
Change during 4 weeks of therapy provided at least 6 months after stroke

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Kinarm: arm position matching task
Time Frame: Change during 4 weeks of therapy provided at least 6 months after stroke
Assessment of limb position sense using a 9-target mirror-matching task on the Kinarm Exoskeleton Lab
Change during 4 weeks of therapy provided at least 6 months after stroke
Kinarm: arm movement matching task
Time Frame: Change during 4 weeks of therapy provided at least 6 months after stroke
Assessment of limb movement sense using a mirror-matching task on the Kinarm Exoskeleton Lab
Change during 4 weeks of therapy provided at least 6 months after stroke
Kinarm: visually guided reaching task
Time Frame: Change during 4 weeks of therapy provided at least 6 months after stroke
Assessment of motor function using a 4-target centre-out reaching task on the Kinarm End-Point Lab
Change during 4 weeks of therapy provided at least 6 months after stroke
Kinarm: working memory task
Time Frame: Change during 4 weeks of therapy provided at least 6 months after stroke
Assessment of working memory on the Kinarm End-Point Lab, by asking the participant to remember the position of 3, 4, 5 or 6 targets simultaneously.
Change during 4 weeks of therapy provided at least 6 months after stroke
Erasmus modified Nottingham sensory assessment
Time Frame: Change during 4 weeks of therapy provided at least 6 months after stroke
Clinical assessment of somatosensory function (including exteroception, proprioception and sensory processing) on an ordinal scale ranging from 0 to 40, with higher scores meaning better performance
Change during 4 weeks of therapy provided at least 6 months after stroke
Tactile discrimination test
Time Frame: Change during 4 weeks of therapy provided at least 6 months after stroke
Clinical assessment of sensory processing with an area under the curve based scoring system, with higher scores meaning better performance
Change during 4 weeks of therapy provided at least 6 months after stroke
Functional tactile object recognition test
Time Frame: Change during 4 weeks of therapy provided at least 6 months after stroke
Clinical assessment of sensory processing on an ordinal scale ranging from 0 to 42, with higher scores meaning better performance
Change during 4 weeks of therapy provided at least 6 months after stroke
Fugl-Meyer upper extremity assessment
Time Frame: Change during 4 weeks of therapy provided at least 6 months after stroke
Clinical assessment of motor function on an ordinal scale ranging from 0 to 66, with higher scores meaning better performance
Change during 4 weeks of therapy provided at least 6 months after stroke
Action research arm test
Time Frame: Change during 4 weeks of therapy provided at least 6 months after stroke
Timed clinical assessment of motor activity performance on an ordinal scale ranging from 0 to 57, with higher scores meaning better performance
Change during 4 weeks of therapy provided at least 6 months after stroke
Sensorimotor action research arm test
Time Frame: Change during 4 weeks of therapy provided at least 6 months after stroke
Timed clinical assessment of sensorimotor performance on an ordinal scale ranging from 0 to 57, with higher scores meaning better performance
Change during 4 weeks of therapy provided at least 6 months after stroke
Montreal cognitive assessment
Time Frame: Change during 4 weeks of therapy provided at least 6 months after stroke
Clinical assessment of cognitive function on an ordinal scale ranging from 0 to 30, with higher scores meaning better performance
Change during 4 weeks of therapy provided at least 6 months after stroke
Star cancellation test
Time Frame: Change during 4 weeks of therapy provided at least 6 months after stroke
Clinical assessment of visuospatial neglect on an ordinal scale ranging from 0 to 54, with higher scores meaning better performance, and a score below 44 indicating the presence of visuospatial neglect
Change during 4 weeks of therapy provided at least 6 months after stroke
Kinarm: sensory processing task
Time Frame: Change in 2 baseline measures taken 2 days apart, at least 6 months after stroke
Newly-developed task on the Kinarm End-Point Lab used to assess passive and active sensory processing
Change in 2 baseline measures taken 2 days apart, at least 6 months after stroke
Kinarm: sensory processing task
Time Frame: Change during the first 2 weeks of a 4-week therapy protocol provided at least 6 months after stroke
Newly-developed task on the Kinarm End-Point Lab used to assess passive and active sensory processing
Change during the first 2 weeks of a 4-week therapy protocol provided at least 6 months after stroke
Kinarm: sensory processing task
Time Frame: Change during the last 2 weeks of a 4-week therapy protocol provided at least 6 months after stroke
Newly-developed task on the Kinarm End-Point Lab used to assess passive and active sensory processing
Change during the last 2 weeks of a 4-week therapy protocol provided at least 6 months after stroke

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 14, 2021

Primary Completion (ACTUAL)

June 13, 2022

Study Completion (ACTUAL)

June 13, 2022

Study Registration Dates

First Submitted

July 11, 2021

First Submitted That Met QC Criteria

August 12, 2021

First Posted (ACTUAL)

August 16, 2021

Study Record Updates

Last Update Posted (ACTUAL)

July 20, 2022

Last Update Submitted That Met QC Criteria

July 19, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Robot-based therapy

Subscribe